Business Wire

Vita Mojo Raises US$30 Million to Help Restaurant and Hospitality Chains in Europe Tackle the Digital Future

30.6.2022 13:00:00 EEST | Business Wire | Press release

Share

Vita Mojo, the European leader in “front-of-house” restaurant software powering digital ordering and the management of smarter, more-efficient kitchen and delivery operations, has raised US$30 million in new financing to refine its product and expand into new markets.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220630005213/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Vita Mojo Co-Founders Nick Popovici (left) and Stefan Catoiu. (Photo: Business Wire)

The funding round was led by global technology investment firm Battery Ventures, an investor in a number of U.S.-based restaurant and hospitality-tech companies including Olo* and CrunchTime! Information Systems*. Battery General Partner Morad Elhafed and Principal Zak Ewen will join Vita Mojo’s board. Vita Mojo – which sells to restaurants, pubs, coffee shops, bakeries and fast-casual eateries – counts large chains among its customer base including Nando’s, GAIL’s Bakery, Le Pain Quotidien, LEON, JKS Group and Neat Burger.

“The headwinds and opportunities facing restaurants today are enormous. Operators are adapting to changing customer preferences around dining and ordering as well as monumental market disruptions – first the pandemic, then supply-chain disruptions and a labour shortage. This has dramatically changed how restaurants operate and shrunk profit margins for those not able to adapt,” said Vita Mojo CEO Nick Popovici, who originally founded the company as a healthy-restaurant chain and then pivoted to restaurant software.

Recent research from Vita Mojo shows over four-fifths (84%) of Generation Z and millennials (82%) would rather visit a restaurant with self-serve kiosks than a restaurant without. According to Popovici, “Digital transformation is essential for the hospitality sector today, and our technology helps companies move forward.”

Vita Mojo also announced new technology that empowers restaurant customers to make better food choices when dining out. A new, integrated feature in the company’s technology lets restaurants accurately and seamlessly display nutrition and allergen information across their menus by pulling the data directly from recipe-management software. A U.K.-wide survey conducted by Vita Mojo earlier this spring found that 43% of customers would be more likely to eat at a restaurant with calorie labelling on the menu.

Vita Mojo is based in London and serves over 130 operators across the U.K. and Europe. The company’s platform enables restaurants to manage their core operations in one integrated system, from digital ordering via their own channels and third-party delivery platforms – such as Just Eat, Deliveroo and Uber Eats – to smarter kitchen and back-of-house management. Unlike most hospitality tech providers who specialise in one element of the restaurant tech stack, Vita Mojo is a powerful, full-suite platform that brings together both customer ordering and kitchen operations.

For customers, Vita Mojo enables self-service ordering from kiosks and customers’ own devices, as well as a more-efficient takeaway experience. On the restaurant-management side, it empowers operators to seamlessly integrate all ordering channels into one system. Vita Mojo clients see an increase of 35% in average order value and an average reduction in labour costs of up to 40%.

“With the funding round complete, now is the time for action,” said Vita Mojo Co-founder and COO Stefan Catoiu. "This investment will accelerate our product roadmap, as well as help upgrade our data and insights features and grow our client success, product and engineering teams. We’re on track to double our headcount over the next year, with the majority of our recruitment focused on taking our client support to the next level.”

Restaurants now realise they can see a significant revenue boost from an integrated, multi-channel ordering system, given the rise in delivery and takeaway orders that has outlasted the pandemic. The vast amounts of data generated by Vita Mojo’s technology, from order to bill, helps restaurants serve customers better and build loyalty by personalising their experience and offering customised marketing based on previous order activity.

“Vita Mojo has a bold vision for the restaurant industry,” said Battery’s Morad Elhafed. “Offering one platform that combines digital ordering with kitchen operations is a valuable proposition that solves the headaches of managing multiple point solutions and systems. Our experience with restaurant tech in the U.S. makes us excited about Vita Mojo’s opportunity in Europe – and its overall mission of taking restaurants to the next level by simplifying their operations and delivering a remarkable experience for customers.”

*For a full list of all Battery investments and exits, click here .

About Vita Mojo

Vita Mojo is a software company revolutionising the hospitality industry. Founded in 2016 by Nick Popovici and Stefan Catoiu, Vita Mojo started life as the UK’s first cashless, cashier-less and digital-only restaurants. They used their experience to build and refine Vita Mojo’s full-suite technology platform which combines everything a restaurant operator needs to thrive: award-winning digital ordering, Point of Sale, delivery and order management, kitchen operations and marketing & growth tools. Today, more than 130 operators across 5 countries (including LEON, Nando’s, Le Pain Quotidien and GAIL’s Bakery) use Vita Mojo to grow sales, streamline their operations and create remarkable customer experiences.

About Battery Ventures

Battery partners with exceptional founders and management teams to developing category-defining businesses in markets including software and services, enterprise infrastructure, consumer technology, healthcare IT and industrial tech/life-sciences tools. Founded in 1983, the firm backs companies at all stages, ranging from seed and early to growth and buyout, and invests globally from offices in Boston, San Francisco, Menlo Park, London New York, and Tel Aviv. Follow the firm on Twitter @BatteryVentures, visit our website at www.battery.com and find a full list of Battery's portfolio companies here.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media Contact:
Stephanie Gnibus
GMK Communications
stephanie@gmkcommunications.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Gurobi Appoints Dr. Pascal Van Hentenryck to Lead AI Innovation Lab17.2.2026 16:00:00 EET | Press release

Gurobi Optimization, LLC, the leader in decision intelligence technology, is pleased to announce that Dr. Pascal Van Hentenryck has joined the company as head of the Gurobi AI Innovation Lab (GAIL). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260217170385/en/ Dr. Pascal Van Hentenryck, Head of AI Innovation Lab, Gurobi Optimization As part of Gurobi’s long-term product and technology strategy, the Gurobi AI Innovation Lab is a focused Research & Development initiative dedicated to advancing the combination of multiple AI technologies with optimization to solve complex, large-scale, and time-critical decision problems. “Pascal brings exceptional leadership across mathematical optimization and complementary AI technologies,” said Dr. Oliver Bastert, CTO, Gurobi Optimization. “While mathematical optimization remains the best approach for most decision problems—as demonstrated by thousands of successful customer implementatio

Watchmaker Genomics Licenses CRISPR-Cas9 Intellectual Property from Caribou Biosciences to Increase Throughput and Reduce Sequencing Cost per Sample17.2.2026 15:00:00 EET | Press release

Watchmaker Genomics, an innovator in high-performance solutions for next-generation sequencing (NGS), today announced a non-exclusive license with Caribou Biosciences, Inc., a leading clinical-stage CRISPR genome-editing biopharmaceutical company, for certain foundational CRISPR-Cas9 intellectual property for use in NGS library preparation. While CRISPR-Cas9 technologies are most commonly associated with their unique ability to find and cut for genome editing, Watchmaker is leveraging it in a fundamentally different way: as a programmable, stoichiometric binding tool to address one of the most persistent and under-optimized steps in NGS workflows – library normalization. “Normalization has quietly become a bottleneck as sequencing throughput has scaled,” said Brian Kudlow, CSO and Founderat Watchmaker Genomics. “This license gives us the freedom to rethink normalization from first principles, using CRISPR-Cas9 in a way that’s orthogonal to editing but highly aligned with modern sequenc

Esri and Pix4D Launch Real-Time Terrestrial Mapping Workflow17.2.2026 15:00:00 EET | Press release

Esri, the global leader in geographic information system (GIS) technology, has launched a terrestrial mapping workflow with Pix4D. A Switzerland-based photogrammetry software company, Pix4D specializes in mobile reality capture and site-digitization. The combined workflow allows field teams to capture and process asset data and manage it within ArcGIS, Esri’s geospatial platform. Field teams use the PIX4Dcatch app with real-time kinematics (RTK) devices to scan trenches and infrastructure. The generated high precision georeferenced records can now be published into Esri’s ArcGIS Online. Scans become 3D models and point clouds, viewable as a Scene Layer. Existing data can also be visualized in augmented reality for instant “as-designed” versus “as-built” verification before closing trenches. “We are focused on turning hidden infrastructure into functional data,” said Andrey Kleymenov, CEO of Pix4D. “By connecting PIX4Dcatch with a compatible RTK device to the Esri ecosystem, we are enab

Compass Pathways Successfully Achieves Primary Endpoint in Second Phase 3 Trial Evaluating COMP360 Psilocybin for Treatment-Resistant Depression17.2.2026 13:30:00 EET | Press release

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, announced today the successful achievement of the primary endpoint in the ongoing Phase 3 COMP006 trial, the second of two Phase 3 trials, which is evaluating two fixed doses of COMP360, a synthetic, proprietary formulation of psilocybin, for treatment-resistant depression (TRD). The primary endpoint was the difference in change from baseline in the Montgomery-Åsberg Depression Rating Scale (MADRS) scores between the 25 mg and 1 mg groups at Week 6. Two fixed doses – administered 3 weeks apart – of COMP360 25 mg versus 1 mg demonstrated a highly statistically significant reduction in symptom severity with a p-value of <0.001 and a clinically meaningful difference of -3.8 points in change at the primary endpoint. Across COMP005 and COMP006 to date, COMP360 is demonstrating a generally well-tolerated and safe profile, with treatment-emergent adverse events (

BeOne Medicines to Present at Upcoming Investor Conferences17.2.2026 13:00:00 EET | Press release

BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the Company will participate in fireside chats at four upcoming investor conferences: TD Cowen 46th Annual Health Care Conference on Monday, March 2, 2026 at 9:10 am ET; Leerink Global Healthcare Conference on Monday, March 9, 2026 at 11:20 am ET; Citizens Life Sciences Conference on Tuesday, March 10, 2026 at 9:35 am ET; and Barclays 28th Annual Global Healthcare Conference on Tuesday, March 10, 2026 at 3:00 pm ET Live webcasts of these events can be accessed from the investors section of the Company’s website at https://ir.beonemedicines.com. Archived replays will be available on the Company’s website. About BeOne Medicines BeOne Medicines is a global oncology company that is discovering and developing innovative treatments for cancer patients worldwide. With a portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel the

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye